[go: up one dir, main page]

AU6140998A - Peptides and peptide-loaded antigen presenting cells for the activation of ctl - Google Patents

Peptides and peptide-loaded antigen presenting cells for the activation of ctl

Info

Publication number
AU6140998A
AU6140998A AU61409/98A AU6140998A AU6140998A AU 6140998 A AU6140998 A AU 6140998A AU 61409/98 A AU61409/98 A AU 61409/98A AU 6140998 A AU6140998 A AU 6140998A AU 6140998 A AU6140998 A AU 6140998A
Authority
AU
Australia
Prior art keywords
ctl
peptides
peptide
activation
presenting cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61409/98A
Inventor
Esteban Celis
Alessandro Sette
John Sidney
Scott Southwood
Van Tsai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of AU6140998A publication Critical patent/AU6140998A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU61409/98A 1997-01-31 1998-01-30 Peptides and peptide-loaded antigen presenting cells for the activation of ctl Abandoned AU6140998A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3669697P 1997-01-31 1997-01-31
US60036696 1997-01-31
PCT/US1998/001959 WO1998033888A1 (en) 1997-01-31 1998-01-30 Peptides and peptide-loaded antigen presenting cells for the activation of ctl

Publications (1)

Publication Number Publication Date
AU6140998A true AU6140998A (en) 1998-08-25

Family

ID=21890106

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61409/98A Abandoned AU6140998A (en) 1997-01-31 1998-01-30 Peptides and peptide-loaded antigen presenting cells for the activation of ctl

Country Status (5)

Country Link
EP (1) EP1012238A4 (en)
JP (1) JP2001509677A (en)
AU (1) AU6140998A (en)
CA (1) CA2278189A1 (en)
WO (1) WO1998033888A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IT1309584B1 (en) * 1999-02-26 2002-01-24 San Raffaele Centro Fond IMMUNOGENIC PEPTIDES DERIVED FROM MAGE-3 PRESENTED BY MHC OF CLASS II AND THEIR USE.
EP1189624A4 (en) * 1999-06-29 2005-02-23 Epimmune Inc Hla binding peptides and their uses
AU1661201A (en) 1999-11-18 2001-05-30 Epimmune, Inc. Heteroclitic analogs and related methods
CA2392764A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
CA2393730A1 (en) * 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
EP1303287A4 (en) * 2000-06-16 2006-02-08 Argonex Pharmaceuticals MHC OUREXPRIMES PEPTIDES ON PROSTATE CANCER CELLS AND METHODS OF USE
EP1312670A4 (en) * 2000-08-16 2005-11-30 Takara Bio Inc PROCESS FOR THE EXTENSIVE CULTURE OF ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES
WO2002020616A1 (en) * 2000-09-01 2002-03-14 Epimmune Inc. Hla-a2.1 binding peptides and their uses
AU2002257647A1 (en) * 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
WO2002080848A2 (en) 2001-04-09 2002-10-17 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
EP1424387B1 (en) 2001-08-15 2009-04-22 Takara Bio Inc. Method of extended culture for antigen-specific cytotoxic t lymphocytes
TWI334442B (en) 2002-03-25 2010-12-11 Takara Bio Inc Process for producing cytotoxic lymphocyte
DK1620456T3 (en) 2003-04-18 2014-04-22 Biotech Synergy Inc HLA-A2 TUMOR-ASSOCIATED ANTIGEN PEPTIDES AND PREPARATIONS
JPWO2005007694A1 (en) * 2003-07-16 2007-09-20 株式会社グリーンペプタイド HER2 / neu peptide and its therapeutic use
EP1666589B1 (en) 2003-08-22 2010-02-17 Takara Bio Inc. Process for producing cytotoxic lymphocytes
EP1715343B1 (en) * 2005-04-20 2009-12-09 F. Hoffmann-La Roche Ag Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
WO2007020880A1 (en) 2005-08-17 2007-02-22 Takara Bio Inc. Method of producing lymphocytes
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
MX2012002365A (en) 2009-08-24 2012-07-17 Baylor College Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses.
CN103906531A (en) 2011-05-26 2014-07-02 金纽斯生物科技投资有限责任公司 Modulated immunodominance therapy
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
CN109182266A (en) 2011-12-12 2019-01-11 细胞药物有限公司 The method of amplifier T cell
PL2812431T3 (en) 2012-02-09 2020-02-28 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
CN108449994B (en) 2015-09-18 2021-10-01 贝勒医学院 Identification of immunogenic antigens from pathogens and correlation with clinical efficacy
CN105175527B (en) * 2015-10-09 2021-06-04 深圳市康尔诺生物技术有限公司 Breast cancer specific heat shock protein complex and application thereof
CN109310709A (en) * 2015-12-30 2019-02-05 细胞基因公司 T lymphocyte production method and T lymphocytes produced therefrom
US12247053B2 (en) 2018-10-26 2025-03-11 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342730T1 (en) * 1992-08-07 2006-11-15 Pharmexa Inc HLA BINDING PEPTIDES AND THEIR USES

Also Published As

Publication number Publication date
WO1998033888A1 (en) 1998-08-06
EP1012238A1 (en) 2000-06-28
CA2278189A1 (en) 1998-08-06
EP1012238A4 (en) 2003-03-05
JP2001509677A (en) 2001-07-24

Similar Documents

Publication Publication Date Title
AU6140998A (en) Peptides and peptide-loaded antigen presenting cells for the activation of ctl
AU7478394A (en) Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
AU4397297A (en) Antibody against human parathormone related peptides
AU7158398A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
AU1682699A (en) Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
AU6095696A (en) Immunogenic peptides of prostate specific antigen
AU1021997A (en) Cd100 antigen and uses therefor
AU2768597A (en) Novel peptides suitable for use in antigen specific immunosuppressive therapy
AU4423799A (en) Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
AU6247898A (en) Stretched fasteners
AU7180294A (en) Reaction cell for protein sequencer and the like
AU4236097A (en) Mhc peptides and methods of use
AU1598500A (en) Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2
AU6649698A (en) Peptide probes to coil proteins and methods for making the same
AU7238098A (en) Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants
AU3305197A (en) Non-activated receptor complex proteins and uses thereof
AU4301100A (en) Isolated peptide of the horny layer and use thereof
AU2408397A (en) Ob protein receptor genes and use of the same
AU7308200A (en) Novel hev antigenic peptide and methods
AUPN024994A0 (en) Assay and peptides for use therein
AU8010698A (en) Method and device for enabling non-destructive determination of the elasticity of materials
AU6301698A (en) Anti-hiv peptides and proteins
AU5956498A (en) Modified treponema pallidum-derived antigen protein
AU8679498A (en) Immunologically privileged cells and uses thereof
AU5915998A (en) Battery belt assembly and related methods